Dioscin: Therapeutic potential for diabetes and complications - 05/01/24
, Weihua Xiao a, b, ⁎ 
Abstract |
Diabetes mellitus is a widespread metabolic disorder with increasing incidence worldwide, posing a considerable threat to human health because of its complications. Therefore, cost-effective antidiabetic drugs with minimal side effects are urgently needed. Dioscin, a naturally occurring compound, helps to reduce the complications of diabetes mellitus by regulating glucose and lipid metabolism, protecting islet β cells, improving insulin resistance, and inhibiting oxidative stress and inflammatory response. Plant-derived dioscin reduces the risk of toxicity and side effects associated with chemically synthesized drugs. It is a promising option for treating diabetes mellitus because of its preventive and therapeutic effects, which may be attributed to a variety of underlying mechanisms. However, data compiled by current studies are preliminary. Information about the molecular mechanism of dioscin remains limited, and no high-quality human experiments and clinical trials for testing its safety and efficacy have been conducted. As a resource for research in this area, this review is expected to provide a systematic framework for the application of dioscin in the treatment of diabetes mellitus and its complications.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Dioscin is a class of natural products with multi-target pharmacological activities. |
• | Dioscin exerts antidiabetic effects through multiple mechanisms. |
• | Dioscin can prevent and treat a variety of diabetes complicationsby regulating various targets and signaling pathways. |
• | Dioscin has shown full therapeutic potential for diabetic-related lung and bone lesions. |
Abbreviations : DM, T1DM, T2DM, IR, IDF, TCM, Dio, TLR4, MyD88, TGF-β, ADME, GLUT-4, GSK-3β, PEPCK, G6Pase, HFD, SREBP-1c, FAS, ACC, SCD1, AMPK, MAPK, C/EBP, PPARγ, IRS, PI3K, Akt/PKB, PA, SIRT1, FoxO1, ROS, PKC, SOD, Nrf2, HO-1, GSH-Px, CAT, MDA, IL-1β, IL-6, TNF-α, IKKβ/IKBβ, NF-κB, JNK, COX2, STZ, TSDN, DKD, CKD, mtDNA, nDNA, mTOR, DN, DPN, DSPN, NGF, PDPN, DC, TGF, NO, sGC, cGMP, PKG, DR, AGEs, NPDR, PDR, VEGF, VEGFR, HRMECs, AS, oxLDL, LOX‑1, DCs, SR-A, DCD, P2×7R, NLRP3, BMD, ASC, RANKL, TRAF6, TSRD, CYP, AhR, DPP-4, GLP-1, SGLT-2
Keywords : Dioscin, Therapeutics, Diabetes mellitus, Diabetic complications
Plan
Vol 170
Article 116051- janvier 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
